Clinical trial registry record

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 22, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04176133
Last registry update
June 22, 2023
Status
Completed
Phase
Phase 2
Sponsor
Robert J. Pignolo
Enrollment
61
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · PREVENTION · DOUBLE
Evidence population
Human clinical study registration
Participants
61
Population
ALL · 65 Years
Duration
2019-10-30 to 2022-03-30
Intervention
Entolimod; Placebo; Influenza vaccine
Comparator
Placebo
Outcomes measured
Change in Anti- A/H1N1 Antibody Titer — Baseline, 1 month; Change in Anti-A/H3N2 Antibody Titer — Baseline, 1 month; Change in Anti-B Antibody Titer — Baseline, 1 month; Adverse Events — 1 year; Time of Onset for Upper-respiratory Infections — 1 year; Upper Respiratory Infections — 1 year; Change in Frailty — baseline, 2 months; Change in 6-minute Walk Test — baseline, 2 months; Change in Grip Strength — baseline, 2 months; Change in Body Mass Index (BMI) — baseline, 2 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Immune ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

immune aging
Read the original source →Export JSON